Md Shakil Ahmed Khan is an emerging scientist whose academic and research journey reflects an unwavering dedication to innovation in molecular medicine and cancer therapeutics. Hailing from the vibrant city of Barishal, Bangladesh, he began his academic pursuit in Biotechnology and Genetic Engineering at the Islamic University, where he laid a strong foundation in molecular biology and biomedical research.
Fuelled by a deep curiosity and passion for translational science, Shakil advanced to pursue his Master’s degree at Seoul National University, South Korea—one of Asia’s leading research institutions. As a member of the Translational Molecular Imaging and Theranostics Laboratory within the Department of Molecular Medicine and Biopharmaceutical Sciences, he engaged in pioneering research at the intersection of nanotechnology and oncology. His master’s thesis, titled “Aptamer-Conjugated Liposome System for Targeting MUC1-Positive Cancer: An In Silico Screening Approach,” focused on developing a precision-targeted nanocarrier system designed to enhance the specificity of doxorubicin delivery to cancer cells. Complementing this work, he contributed to a collaborative project on “Development of Cationic pH-Responsive Albumin Binding Ligands with Enhanced Blood Half-Life for Cancer Theranostics,” highlighting his ability to integrate computational modeling with experimental validation.
Building on this expertise, Shakil is currently pursuing his Ph.D. at Texas Tech University (USA), where his research explores the immunomodulatory roles of cancer-derived mirtrons—a unique class of small RNAs capable of forming G-quadruplex structures that regulate immune signaling through Toll-like receptor 7 (TLR7). His doctoral work integrates RNA biology, nanomedicine, and cancer immunology to design RNA-based therapeutic strategies for tumor immune modulation and targeted delivery.
Earlier in his academic career, Shakil conducted impactful undergraduate research on the prevalence of multidrug-resistant Acinetobacter baumannii in hospital environments and the computational formulation of multi-peptide vaccines against the Crimean–Congo hemorrhagic fever virus, demonstrating his early commitment to addressing global biomedical challenges.
From Barishal to Seoul, and now to Texas, Md Shakil Ahmed Khan’s journey exemplifies perseverance, intellectual curiosity, and scientific innovation. With a growing portfolio of publications in nanomedicine, computational biology, and cancer therapeutics, he continues to contribute meaningfully to the evolving field of molecular medicine, aspiring to bridge RNA biology and translational nanotechnology for next-generation cancer therapies.
Once upon a time, a devastating event shook my family to its core. In 2015, we received the heartbreaking news of my uncle's passing, a victim of liver cancer. It was a moment that left an indelible mark on my soul, as I witnessed firsthand the profound impact cancer can have on a family's emotional and financial well-being. The loss plunged my uncle's loved ones into a state of financial struggle, leaving them teetering on the edge of poverty. This poignant experience ignited within me a deep-seated desire to delve into the realm of cancer research, viewing it through a practical lens and analytical framework.
Growing up in an underdeveloped neighborhood, I was all too familiar with the various forms of disease that afflicted the community. Access to adequate healthcare was a luxury most couldn't afford, and the cost of cancer treatment seemed insurmountable. It became my fervent wish to contribute to a world where cancer therapies are effective, affordable, and accessible to all.
During my school days, a science fiction book captured my imagination. Penned by Dr. Mohammad Zafar Iqbal, a renowned professor and writer in our country, it explored the realm of genetic engineering and its potential to eradicate infectious diseases, including cancer. This literary journey sowed the seeds of ambition within me, igniting a passion to become a genetic engineer. Though I qualified for admission to several prestigious universities for my bachelor's degree, I chose the Islamic University due to its esteemed "Biotechnology and Genetic Engineering" department, a perfect match for my childhood dream.
However, the transition to an English medium of instruction proved challenging in my sophomore year. I found myself struggling to adapt and keep pace with the academic demands. Determined to overcome these obstacles, I immersed myself in an array of biology books and research articles. Attending monthly seminars led by prominent researchers and faculty members became a regular part of my routine. These enlightening sessions not only expanded my knowledge but also fueled my growing interest in research.
It was during my senior year that the course on oncology opened up a whole new world of questions within me. I delved deep into books that shed light on the subject, such as Bruce Alberts' "Molecular Biology of the Cell," L M Franks' "Introduction to the Cellular and Molecular Biology of Cancer," and Robert A Weinberg's "The Biology of Cancer." These invaluable resources laid a solid foundation in oncology and further fueled my curiosity to unravel the mysteries that surround the disease. Attending seminars and symposiums featuring internationally renowned scientists discussing key questions in cancer research broadened my perspectives and ignited a particular fascination with cancer immunology. As I delved into metastasis, carcinogenic agents, oncogenes, host-tumor interactions, various therapies, cancer genome sequencing, and more, I became resolute in my dedication to unraveling the complexities of cancer.
My journey thus far has been one of resilience, fueled by personal experiences, literary inspiration, and a burning desire to combat cancer. It has instilled a steadfast commitment to making a difference through rigorous research and scientific exploration. As I witnessed the devastating toll cancer takes on countless lives, I realized that my true calling lies in pioneering advancements that will one day render cancer more manageable and offer hope to those who need it most.